{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:17:57Z","timestamp":1790983077700,"version":"4.1.0"},"reference-count":20,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"7","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurosurg Case Lessons"],"published-print":{"date-parts":[[2026,8,17]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Bevacizumab (BEV) has been associated with posterior reversible encephalopathy syndrome (PRES). Central-variant PRES (cvPRES), involving the thalami and periventricular regions, can mimic glioblastoma (GBM) recurrence. Few reports have described this pattern assessed by serial quantitative apparent diffusion coefficient (ADC) measurement with BEV continuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBSERVATIONS<\/jats:title>\n                    <jats:p>A 36-year-old woman with IDH-mutant GBM of the left frontal lobe, treated with resection, radiotherapy, temozolomide, and subsequently BEV at recurrence, presented 6 weeks after her ninth BEV cycle with impaired consciousness and gait disturbance. Family blood pressure (BP) records revealed systolic variability of 90\u2013200 mm Hg with temporal correlation between systolic peaks and neurological worsening. MRI showed periventricular fluid-attenuated inversion recovery hyperintensity extending into the bilateral medial thalami, faint patchy enhancement, and elevated ADC. Symptoms improved within days of antihypertensive optimization; at 5 months, imaging nearly resolved and quantitative ADC measurement showed near-complete normalization (normalized ADC [nADC] 1.42 \u2192 1.00). BEV was continued under strict BP management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LESSONS<\/jats:title>\n                    <jats:p>In GBM patients on BEV, a lesion with 1) central\/periventricular\/thalamic distribution, 2) absent nodular\/ring enhancement, 3) elevated ADC, 4) temporal correlation between BP fluctuation and symptoms, and 5) prompt reversibility with antihypertensive optimization should suggest cvPRES over recurrence. ADC normalization supports reversibility, and BEV continuation under strict BP control is reasonable in recurrent GBM.<\/jats:p>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/thejns.org\/doi\/10.3171\/CASE26614\">https:\/\/thejns.org\/doi\/10.3171\/CASE26614<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3171\/case26614","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:01:05Z","timestamp":1787097665000},"source":"Crossref","is-referenced-by-count":1,"title":["Central-variant posterior reversible encephalopathy syndrome mimicking tumor progression in a glioblastoma patient on bevacizumab: illustrative case"],"prefix":"10.3171","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6216-7119","authenticated-orcid":true,"given":"Yusuke","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Showa Medical University School of Medicine, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Kawauchi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Showa Medical University School of Medicine, Tokyo"},{"name":"Department of Neurosurgery, Kashiwa Tanaka Hospital, Chiba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Showa Medical University School of Medicine, Tokyo"},{"name":"Brain Function Analysis and Digital Medicine Research Institute, Showa Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3845-5205","authenticated-orcid":true,"given":"Tomomi","family":"Yoshiyama","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Showa Medical University School of Medicine, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuya","family":"Natori","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Showa Medical University School of Medicine, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Tanioka","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Showa Medical University School of Medicine, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Morofuji","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Showa Medical University School of Medicine, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"issue":"8","key":"bib1","series-title":"N Engl J Med","first-page":"709","article-title":"Bevacizumab plus \u00adradiotherapy\u2013temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","unstructured":"Chinot OLWick WMason WBevacizumab plus \u00adradiotherapy\u2013temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722. doi:10.1056\/NEJMoa1308345"},{"issue":"8","key":"bib2","series-title":"N Engl J Med","first-page":"699","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","unstructured":"Gilbert MRDignam JJArmstrong TSA randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708. doi:10.1056\/NEJMoa1308573"},{"issue":"9","key":"bib3","series-title":"Lancet Oncol","first-page":"943","article-title":"Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial","volume":"15","author":"Taal","year":"2014","unstructured":"Taal WOosterkamp HMWalenkamp AMESingle-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15(9):943-953. doi:10.1016\/S1470-2045(14)70314-6"},{"issue":"20","key":"bib4","series-title":"N Engl J Med","first-page":"1954","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","unstructured":"Wick WGorlia TBendszus MLomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017;377(20):1954-1963. doi:10.1056\/NEJMoa1707358"},{"issue":"7","key":"bib5","series-title":"JAMA Oncol","first-page":"1003","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","unstructured":"Reardon DABrandes AAOmuro AEffect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(7):1003-1010. doi:10.1001\/jamaoncol.2020.1024"},{"issue":"5","key":"bib6","series-title":"JAMA","first-page":"487","article-title":"Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis","volume":"305","author":"Ranpura","year":"2011","unstructured":"Ranpura VHapani SWu S.Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA. 2011;305(5):487-494. doi:10.1001\/jama.2011.51"},{"issue":"10","key":"bib7","series-title":"Neuro Oncol","first-page":"1203","article-title":"Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors","volume":"14","author":"Armstrong","year":"2012","unstructured":"Armstrong TSWen PYGilbert MRSchiff D.Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol. 2012;14(10):1203-1214. doi:10.1093\/neuonc\/nor223"},{"issue":"8","key":"bib8","series-title":"N Engl J Med","first-page":"494","article-title":"A reversible posterior leukoencephalopathy syndrome","volume":"334","author":"Hinchey","year":"1996","unstructured":"Hinchey JChaves CAppignani BA reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494-500. doi:10.1056\/NEJM199602223340803"},{"issue":"9","key":"bib9","series-title":"Lancet Neurol","first-page":"914","article-title":"Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions","volume":"14","author":"Fugate","year":"2015","unstructured":"Fugate JERabinstein AA.Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914-925. doi:10.1016\/S1474-4422(15)00111-8"},{"issue":"6","key":"bib10","series-title":"AJNR Am J Neuroradiol","first-page":"1036","article-title":"Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features","volume":"29","author":"Bartynski","year":"2008","unstructured":"Bartynski WS.Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008;29(6):1036-1042. doi:10.3174\/ajnr.A0928"},{"issue":"3","key":"bib11","series-title":"AJR Am J Roentgenol","first-page":"631","article-title":"Central-variant posterior reversible encephalopathy syndrome: brainstem or basal ganglia involvement lacking cortical or subcortical cerebral edema","volume":"201","author":"McKinney","year":"2013","unstructured":"McKinney AMJagadeesan BDTruwit CL.Central-variant posterior reversible encephalopathy syndrome: brainstem or basal ganglia involvement lacking cortical or subcortical cerebral edema. AJR Am J Roentgenol. 2013;201(3):631-638. doi:10.2214\/AJR.12.9677"},{"key":"bib12","series-title":"Front Neurol","first-page":"460","article-title":"Assessment of glioblastoma response in the era of bevacizumab: longstanding and emergent challenges in the imaging evaluation of pseudoresponse","volume":"10","author":"Arevalo","year":"2019","unstructured":"Arevalo ODSoto CRabiei PAssessment of glioblastoma response in the era of bevacizumab: longstanding and emergent challenges in the imaging evaluation of pseudoresponse. Front Neurol. 2019;10:460. doi:10.3389\/fneur.2019.00460"},{"issue":"2","key":"bib13","series-title":"Neurotherapeutics","first-page":"307","article-title":"Modified criteria for radiographic response assessment in glioblastoma clinical trials","volume":"14","author":"Ellingson","year":"2017","unstructured":"Ellingson BMWen PYCloughesy TF.Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics. 2017;14(2):307-320. doi:10.1007\/s13311-016-0507-6"},{"issue":"9","key":"bib14","series-title":"N Engl J Med","first-page":"980","article-title":"Reversible posterior leukoencephalopathy syndrome and bevacizumab","volume":"354","author":"Glusker","year":"2006","unstructured":"Glusker PRecht LLane B.Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006;354(9):980. doi:10.1056\/NEJMc052954"},{"issue":"10","key":"bib15","series-title":"Arch Neurol","first-page":"1475","article-title":"Reversible posterior leukoencephalopathy syndrome after bevacizumab\/FOLFIRI regimen for metastatic colon cancer","volume":"63","author":"Allen","year":"2006","unstructured":"Allen JAAdlakha ABergethon PR.Reversible posterior leukoencephalopathy syndrome after bevacizumab\/FOLFIRI regimen for metastatic colon cancer. Arch Neurol. 2006;63(10):1475-1478. doi:10.1001\/archneur.63.10.1475"},{"issue":"28","key":"bib16","series-title":"J Clin Oncol","first-page":"e739","article-title":"Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma","volume":"29","author":"Lou","year":"2011","unstructured":"Lou ETurner SSumrall ABevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. J Clin Oncol. 2011;29(28):e739-e742. doi:10.1200\/JCO.2011.36.1865"},{"issue":"1","key":"bib17","series-title":"J Neuroradiol","first-page":"36","article-title":"Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse","volume":"46","author":"Auer","year":"2019","unstructured":"Auer TABreit HCMarini FEvaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse. J Neuroradiol. 2019;46(1):36-43. doi:10.1016\/j.neurad.2018.04.002"},{"issue":"4","key":"bib18","series-title":"Neurooncol Pract","first-page":"184","article-title":"Primary brain tumors and posterior reversible encephalopathy syndrome","volume":"1","author":"Kamiya-Matsuoka","year":"2014","unstructured":"Kamiya-Matsuoka CCachia DOlar AArmstrong TSGilbert MR.Primary brain tumors and posterior reversible encephalopathy syndrome. Neurooncol Pract. 2014;1(4):184-190. doi:10.1093\/nop\/npu024"},{"issue":"2","key":"bib19","series-title":"J Neurooncol","first-page":"237","article-title":"Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma","volume":"99","author":"Zuniga","year":"2010","unstructured":"Zuniga RMTorcuator RJain RRebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J Neurooncol. 2010;99(2):237-242. doi:10.1007\/s11060-010-0121-0"},{"issue":"6","key":"bib20","series-title":"Neuro Oncol","first-page":"823","article-title":"Implications of bevacizumab discontinuation in adults with recurrent glioblastoma","volume":"16","author":"Anderson","year":"2014","unstructured":"Anderson MDHamza MAHess KRPuduvalli VK.Implications of bevacizumab discontinuation in adults with recurrent glioblastoma. Neuro Oncol. 2014;16(6):823-828. doi:10.1093\/neuonc\/nou021"}],"container-title":["Journal of Neurosurgery: Case Lessons"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg-case-lessons\/12\/7\/article-CASE26614.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg-case-lessons\/12\/7\/article-CASE26614.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg-case-lessons\/12\/7\/article-CASE26614.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:01:06Z","timestamp":1787097666000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg-case-lessons\/12\/7\/article-CASE26614.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":20,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.3171\/case26614","relation":{},"ISSN":["2694-1902"],"issn-type":[{"value":"2694-1902","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]}}}